Gene Therapies
Therapy
Health

Spark Therapeutics

$113.53
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.53 (0.47%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell ONCE and other stocks, options, ETFs, and crypto commission-free!

About

Spark Therapeutics, Inc. engages in the research, development, and commercialization of gene therapies. Its product portfolio intends to treat inherited retinal sickness, liver-mediated, and neurodegenerative diseases. Read More The company was founded by Jean Bennett, Beverly Davidson, Katherine A. High, Jeffrey D. Marrazzo, J. Fraser Wright, and Jennifer Wellman on March 13, 2013 and is headquartered in Philadelphia, PA.

Employees
368
Headquarters
Philadelphia, Pennsylvania
Founded
2013
Market Cap
4.26B
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
909.06K
High Today
$113.56
Low Today
$113.10
Open Price
$113.10
Volume
977.74K
52 Week High
$114.20
52 Week Low
$34.53

Collections

Gene Therapies
Therapy
Health
Research And Development
Biotechnology
Technology

News

Seeking AlphaMar 20

Roche: Spark Deal Pricey But Accretive

No financial impact near term but clear cost synergies in the medium-long term, while the deal would ensure growth in the future.

104
MarketBeatMar 16

Stock Price, News, & Analysis for Spark Therapeutics

Spark Therapeutics, Inc. focuses on the development of gene therapy products for patients suffering from debilitating genetic diseases. Its products include LUXTURNA (voretigene neparvovec) for the treatment of patients with confirmed biallelic RPE65 mutation-associated retinal dystrophy and viable retinal cells. The company's gene therapy product candidates comprise SPK-8011 and SPK-8016 for hemophilia; SPK-7001 for choroideremia; and SPK-9001 for hemophilia B. It is also developing other liver-directed ge...

2
Yahoo FinanceMar 12

SPARK THERAPEUTICS, INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation Of Buyout

WILMINGTON, Del., March 12, 2019 (GLOBE NEWSWIRE) -- Rigrodsky & Long, P.A.: Do you own shares of Spark Therapeutics, Inc. (NASDAQ GS: ONCE )? Did you purchase any of your shares prior to February 25, 2019? Do you think the proposed buyout is fair? Do you want to discuss your rights? Rigrodsky & Long, P.A. announces that it is investigating potential legal claims against the board of directors of Spark Therapeutics, Inc. (“Spark” or the “Company”) (NASDAQ GS: ONCE) regarding possible breach...

189

Earnings

-$1.90
-$1.30
-$0.70
-$0.10
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
Actual
Expected May 7, Pre-Market
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.